SOURCE: Seegene, Inc.

September 11, 2007 09:44 ET

Seegene Introduces a Diagnostic Test Kit Capable of Detecting 18 Different Virus- and Bacteria-Born Respiratory Infections in a Single Tube

Seeplex® 18-plex Respiratory Test Sets a New Standard for Detecting All Major Respiratory Pathogens in a Highly Economical Format

ROCKVILLE, MD--(Marketwire - September 11, 2007) - With another potentially virulent flu season approaching, Seegene today introduced a breakthrough multiplex-formatted diagnostic test covering the most common virus and bacteria respiratory infections in a single reaction tube. The Seeplex® 18-plex Respiratory Test is the only diagnostic test capable of simultaneously detecting 18 of the most prevalent respiratory infections -- both virus and bacteria born -- in a single test. The Seeplex® 18-plex Respiratory Test robustly detects 11 different respiratory RNA viruses, 2 DNA viruses, and 5 pneumonia bacteria from samples including nasopharyngeal aspirates, nasopharyngeal swabs and bronchoalveolar lavage.

By enabling healthcare personnel to test for 18 different pathogens for the cost similar to testing for a single pathogen, the Seeplex® 18-plex Respiratory Test breaks the mold of a 'single pathogen, single test' testing regime and high false positives/negatives results associated conventional multiplexing. Traditional tests, such as viral culture and Ag-Ab test, are laborious, time consuming and cost inefficient. The Seeplex® 18-plex Respiratory Test eliminates these drawbacks by multiplexing without cross reactivity and achieving rapid test results at a minimal cost per test, thus setting a new standard for the most economical method of choice for molecular diagnostics of respiratory infections.

The Seeplex® 18-plex Respiratory Test detects Influenza A virus; Influenza B virus; Human respiratory syncytial virus A; Human respiratory syncytial virus B; Human parainfluenzae virus 1; Human parainfluenzae virus 2; Human parainfluenzae virus 3; Human coronavirus 229E/NL63; Human coronavirus OC43/HKU1; Human rhinovirus; Human enterovirus; Human adenovirus; Human bocavirus; Legionella pneumoniae; Streptococcus pneumoniae; Chlamydophila pneumoniae; Haemophilus influenzae; Mycoplasma pneumoniae.

The Seeplex® 18-plex Respiratory Test aspires to become an essential tool for active surveillance and treatment of respiratory illnesses. The use of this new diagnostic test enables healthcare personnel to rapidly determine whether a patient's respiratory ailment is caused by a virus or bacteria, and subsequently prescribe the best course of treatment whether an antibiotic, antiviral or bed rest.

"Our new 18-plex Respiratory Test is what the clinical healthcare industry has been asking for -- the ability to routinely test for a wide spectrum of respiratory pathogens in a single test, at the price of a single pathogen test," stated Jong-Yoon Chun, Founder and Chief Executive Officer, Seegene. "Like our other commercially available tests, notably the recently introduced 18-plex test for human Papillomaviruses, our new respiratory test is simply performed with one multiplex PCR in a single tube and capillary electrophoresis for automated detection of pathogens. These tests use Seegene's proprietary DPO™ (Dual Priming Oligo) primer system, ensuring test reproducibility, specificity and sensitivity.

About Seeplex® System: Frontier of Multi-pathogen Detection

Seeplex® is a breakthrough multiplexing PCR technology that enables a new standard in simultaneous multi-pathogen detection. Seeplex works in combination with automatic detection systems such as Capillary Electrophoresis and delivers a benchmark in testing accuracy, efficiency and cost-effectiveness.

About Seegene

Seegene, Inc. is pioneering the field of multi-pathogen testing. Seegene applies its novel and proprietary Seeplex system utilizing "DPO (Dual Priming Oligo)" and "ACP (Annealing Control Primer)" to create multi-pathogen tests delivering maximum specificity, reproducibility and sensitivity. With over 260 citations and several patents and patents pending, Seegene has been offering advanced molecular diagnostics services to over 1,000 major global institutes in more than 25 countries. Seegene is actively working with both the scientific and OEM business community. Seegene's mission is to integrate Seeplex with disease diagnostics to provide a new guideline for effectively treating patients. Seegene was founded in 2000 and is based in Rockville, MD and Seoul, Korea. For more information please visit www.seegene.com.

Contact Information

  • Contacts:
    Jessica Joung
    Seegene Inc.
    301-762-9066
    Email Contact

    or

    Constantine Theodoropulos
    Boston Communications
    617-292-7319
    Email Contact